Related Experiment Video

Updated: Feb 8, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Bahar Laderian1, Tito Fojo2

  • 1Division of Hematology Oncology, Department of Medicine, Columbia University Medical Center, New York, NY.

Seminars in Oncology
|June 25, 2018
PubMed

Insights

New breast cancer drugs, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, offer new treatment options. This review compares palbociclib, ribociclib, and abemaciclib for metastatic breast cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast cancer remains a significant global health concern, necessitating novel therapeutic strategies.
  • Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors represent a promising new class of cancer drugs impacting breast cancer treatment.

Purpose of the Study:

  • To compare and contrast three approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib.
  • To discuss the role of these agents in the management of metastatic breast cancer.

Main Methods:

  • Review of regulatory-approved CDK4/6 inhibitors for metastatic breast cancer.
  • Comparative analysis of palbociclib, ribociclib, and abemaciclib.

Main Results:

  • Palbociclib was the first CDK4/6 inhibitor approved for breast cancer.
  • Ribociclib and abemaciclib are subsequent "me-too" therapies approved for metastatic breast cancer.
  • These agents are increasingly utilized in oncological practice.

Conclusions:

  • CDK4/6 inhibitors are an important advancement in breast cancer therapy.
  • The comparison of palbociclib, ribociclib, and abemaciclib provides insights into their clinical application.
  • The emergence of these targeted therapies highlights the evolving landscape of cancer treatment.
Keywords:
AbemaciclibCDK 4CDK 4 inhibitorsCDK 6CDK 6 inhibitorsCDK4/6 inhibitorsFDA approvalsPalbociclibRibociclibme-too cancer therapiesretinoblastomaretinoblastoma protein

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.9K
An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis08:11

An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis

Published on: August 14, 2016

32.6K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Therapeutic Communication01:30

Therapeutic Communication

Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.5K
Persuasion Strategies01:52

Persuasion Strategies

Researchers have tested many persuasion strategies, including the foot-in-the door and the door-in-the-face techniques, in a variety of contexts. Ultimately, the principles are effective in selling products and changing people’s attitude, ideas, and behaviors (Cialdini & Goldstein, 2004).
43.5K